Advertisement

Comparison of RANKL expression, inflammatory markers, and cardiovascular risk in patients with acute coronary syndrome with and without rheumatoid arthritis

  • Velichka PopovaEmail author
  • Zaprin Vazhev
  • Mariela Geneva-Popova
  • Anastas Batalov
Comorbidities

Abstract

The mechanisms responsible for increased cardiovascular risk in patients with rheumatoid arthritis (RA) involve local and systemic inflammatory processes. We aimed to compare inflammatory markers and mortality risk in patients with acute coronary syndrome (ACS) with and without RA. The study involved 95 ACS patients (46 with RA and 49 without RA) and 40 healthy controls. Serum levels of Receptor Activator of Nuclear Factor Kappa B Ligand (sRANKL), Osteoprotegerin (sOPG), high-sensitivity C-reactive protein (hs-CRP) and high-sensitivity Tropinin I (hs-TnI) were tested in all participants. Additionally, ACS patients were assessed on RANKL expression (exRANKL) on coronary arteries and mortality risk on the Global Registry of Acute Coronary Events scale (GRACE). exRANKL was established in 35 (76%) ACS patients with RA, vs. 19 (39%) patients without RA, p < 0.001. RA patients had significantly higher levels of sRANKL and sOPG at 24 h and 48 h compared to ACS patients without RA and healthy controls (sRANKL 24 h: 121.33 vs. 51.67 vs. 36.94, p = 0.019; sRANKL 48 h: 89.21 vs. 36.95 vs. 36.94, p = 0.004; sOPG 24 h: 207.71 vs. 69.39 vs. 111.91, p < 0.001; sOPG 48 h: 143.36 vs. 69.38 vs. 111.91, p < 0.001). RA patients had significantly higher RANKL:OPG ratio at 48 h (0.062 vs. 0.53 vs. 0.33, p < 0.001), hs-CRP (28.82 vs. 23.67 vs. 2.60, p < 0.001) and hs-TnI (0.90 vs. 0.76 vs. 0.012). GRACE risk score was significantly higher in RA patients vs. those without RA (140.45 vs. 125.50, p = 0.030) and correlated with exRANKL, RANKL:OPG, hs-CRP, and hs-TnI. Our results indicate that exRANKL, inflammatory markers and mortality risk are amplified in ACS patients with RA compared to ACS patients without RA.

Keywords

Acute coronary syndrome Rheumatoid arthritis Inflammatory biomarkers Mortality RANKL GRACE 

Notes

Funding

None.

Compliance with ethical standards

Ethical approval

All procedures were conducted in accordance with the WMA Declaration of Helsinki (1964) and approved by the local research ethics committee at the Medical University in Plovdiv.

Conflict of interest

All authors declare that they have no conflict of interest.

Informed consent

Informed consent was obtained from each participant involved in this research.

References

  1. 1.
    Cimbrone A (1995) Vascular endothelium: an integrator of pathophysiologic stimuli in atherosclerosis. Am J Cardiol 75:67–70CrossRefGoogle Scholar
  2. 2.
    Faccini A, Kaski C, Camici G (2016) Coronary microvascular dysfunction in chronic inflammatory rheumatoid disease. Eur Heart J 37(23):1799–1806CrossRefGoogle Scholar
  3. 3.
    Gasparyan AY, Stavropoulos-Kalinoglou A, Mikhailidis P, Toms E, Douglas M, Kitas D (2010) The rationale for comparative studies of accelerated atherosclerosis in rheumatic diseases. Curr Vasc Pharmacol 4:437–449CrossRefGoogle Scholar
  4. 4.
    Avina-Zubieta A, Choi K, Sadatsafavi M, Etminan M, Esdaile M, Lacaille D (2008) Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheumatol 59(12):1690–1697CrossRefGoogle Scholar
  5. 5.
    Gasparyan AY (2012) Cardiovascular risk and inflammation: pathophysiological mechanisms, drug design, and targets. Curr Pharm Design 18(11):1447–1449CrossRefGoogle Scholar
  6. 6.
    Castellon X, Bogdanova V (2013) Screening for subclinical atherosclerosis by noninvasive methods in asymptomatic patients with risk factors. Clin Interv Aging 8:573–580CrossRefGoogle Scholar
  7. 7.
    Wallberg-Jonsson S, Ohman M, Dahlqvist S (1997) Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J Rheumatol 24(3):445–451Google Scholar
  8. 8.
    Wang J, Tan G-J, Han L-H, Bai Y-Y, He M, Liu H-B (2017) Novel biomarkers for cardiovascular risk prediction. J Geriatr Cardiol 2:135–150Google Scholar
  9. 9.
    Patterson CC, Blankenberg S, Ben-Shlomo Y, Heslop L, Bayer A, Lowe G, Zeller T, Gallacher J, YoungI Yarnell J (2015) Which biomarkers are predictive specifically for cardiovascular or for non-cardiovascular mortality in men? Evidence from the Caerphilly Prospective Study (CaPS). Int J Cardiol 201:113–118CrossRefGoogle Scholar
  10. 10.
    Schoppet M, Preissner K, Hofbaue L (2002) RANK ligand and osteoprotegerin paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol 22:549–553CrossRefGoogle Scholar
  11. 11.
    Geusens P (2012) The role of RANK ligand/osteoprotegerin in rheumatoid arthritis. Ther Adv Musculoskelet Dis. 4(4):225–233CrossRefGoogle Scholar
  12. 12.
    Montecucco F, Steffens S, Mach F (2007) The Immune response is involved in atherosclerotic plaque calcification: could the RANKL/RANK/OPG system be a marker of plaque instabilitiy? Clin Dev Immunol.  https://doi.org/10.1155/2007/75805 Google Scholar
  13. 13.
    Mohammadpour AH, Shamsara J, Nazemi S, Ghadirzadeh S, Shahsav S, Ramezani M (2012) Evaluation of RANKL/OPG serum concentration ratio as a new biomarker for coronary artery calcification: a pilot study. Thrombosis.  https://doi.org/10.1155/2012/306263 Google Scholar
  14. 14.
    Sandberg W, Yndestad A, Øie E, Smith C, Ueland T, Ovchinnikova O et al (2006) Enhanced T-cell expression of RANK ligand in acute coronary syndrome possible role in plaque destabilization. Arterioscler Thromb Vasc Biol 26:85–863CrossRefGoogle Scholar
  15. 15.
    Crisafulli A, Micari A, Altavilla D, Saporito F, Sardella A, Passaniti M, Raffa S, Danneo G, Lucà F, Mioni C, Arrigo F, Squadrito F (2005) Serum levels of osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction. Clin Sci 109:389–395CrossRefGoogle Scholar
  16. 16.
    Wilson AM, Ryan MC, Boyle AJ (2005) The novel role of C-reactive protein in cardiovascular disease: risk marker or pathogen. Int J Cardiol 106(3):291–297CrossRefGoogle Scholar
  17. 17.
    Everett BM, Brooks MM, Vlachos HEA, Chaitman BR, Frye RL, Bhatt DL (2015) Troponin and cardiac events in stable ischemic heart disease and diabetes. N Engl J Med 373:610–620CrossRefGoogle Scholar
  18. 18.
    Cullen L, Mueller C, Parsonage WA et al (2013) Validation of high-sensitivity troponin I in a 2-hour diagnostic strategy to assess 30-day outcomes in emergency department patients with possible acute coronary syndrome. J Am Coll Cardiol 62(14):1242–1249CrossRefGoogle Scholar
  19. 19.
    Thygesen K, Mair J, Giannitsis E, Mueller C, Lindahl B, Blankenberg S, Huber K, Plebani M, Biasucci L, Tubaro M (2012) How to use high-sensitivity cardiac troponins in acute cardiac care. Eur Heart J 33(18):2252–2257CrossRefGoogle Scholar
  20. 20.
    Huang W, Fitzgerald G, Goldberg J, Gore J, McManus H, Awad H, Waring E, Allison J, Saczynski S, Kiefe I, Fox A, Anderson A, McManus D (2016) Performance of the GRACE risk score 2.0 simplified algorithm for predicting 1—year death after hospitalization for an acute coronary syndrome in a contemporary multiracial cohort. Am J Cardiol 118(8):1105–1110CrossRefGoogle Scholar
  21. 21.
    IBM Corp. Released (2016). IBM SPSS statistics for Windows, version 24.0. Armonk, IBMCorpGoogle Scholar
  22. 22.
    Bernardes M, Vieira TS, Martins MJ, Lucas R, Costa L, Pereira JG, Ventura F, Martins E (2017) Myocardial perfusion in rheumatoid arthritis patients: associations with traditional risk factors and novel biomarkers. Biomed Res J.  https://doi.org/10.1155/2017/6509754 Google Scholar
  23. 23.
    Remuzgo-Martínez S, Genre F, López-Mejías R, Ubilla B, Mijares V, Pina T, Corrales A, Blanco R, Martín J, Llorca J, González-Gay M (2016) Expression of osteoprotegerin and its ligands, RANKL and TRAIL in rheumatoid arthritis. Sci Rep.  https://doi.org/10.1038/srep29713 Google Scholar
  24. 24.
    Gerber TC (2009) Diagnostic and prognostic implications of coronary artery calcification detected by computed tomography. Calcif Tissue Int 91:123–137Google Scholar
  25. 25.
    Gupta S, Gupta VK, Arora S (2013) Relationship of high-sensitive C-reactive protein with cardiovascular risk factors, clinical presentation and angiographic profile in patients with acute coronary syndrome: an Indian perspective. Indian Heart J 65(3):359–365CrossRefGoogle Scholar
  26. 26.
    Milano SS, de Moura OV, Augusto A, Bordin S, Marques GL (2018) C-reactive protein is a predictor of mortality in ST-segment elevation acute myocardial infarction. Int J Cardiovasc Sci.  https://doi.org/10.5935/2359-4802.20180086 Google Scholar
  27. 27.
    Kaptoge S, Di Angelantonio E, Pennells L, Wood AM, White IR, Gao P, Danesh J (2012) C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med 367(14):1310–1320CrossRefGoogle Scholar
  28. 28.
    Underhill HR, Yuan C, Yarnykh VL, Chu B, Oikawa M, Polissar NL, Schwartz SM, Jarvik GP, Hatsukami TS (2009) Arterial remodeling in corrected subclinical carotid artery disease. JACC Cardiovasc Imaging 2(12):1381–1389CrossRefGoogle Scholar
  29. 29.
    Freek WV (2015) The GRACE registry: how real-life evidence contributes to acute coronary syndrome guidelines. Euro Heart J Suppl.  https://doi.org/10.1093/eurheartj/suv039 Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Faculty of Medicine, Department of Rheumatology, Clinic of Rheumatology, UMHAT “Kaspela”Medical University of PlovdivPlovdivBulgaria
  2. 2.Faculty of Medicine, Department of Cardiosurgery, Clinic of Cardiac Surgery and Vessels Surgery, UMHAT “Sv.Georgy”Medical University of PlovdivPlovdivBulgaria
  3. 3.Faculty of Medicine, Department of Rheumatology, Clinic of Rheumatology, UMHAT “Sv. Georgy”Medical University of PlovdivPlovdivBulgaria

Personalised recommendations